Patents Issued in August 27, 2019
  • Patent number: 10391103
    Abstract: Disclosed are a ferroporphyrin solid dispersion, preparation method therefor and a pharmaceutical composition comprising the solid dispersion, wherein the weight ratio of ferroporphyrin to the carrier material in the dispersion is 1:1-1:10. The solid dispersion of the present invention masks the undesirable taste of ferroporphyrin, ameliorates irritation thereof to the digestive tract, and at the same time increases the solubility thereof and improves the bioavailability thereof.
    Type: Grant
    Filed: November 17, 2014
    Date of Patent: August 27, 2019
    Assignee: SINOTHERAPEUTICS INC.
    Inventors: Larry Yun Fang, Jiansheng Wan, Kun Li, Maojian Gu
  • Patent number: 10391104
    Abstract: The present invention discloses an application of an antidepressant compound in preparation of antidepressant drugs and antidepressant health-care foods, where the antidepressant compound has a structure represented by formula I. The antidepressant compound serves as the only active ingredient or one of active ingredients of antidepressant health-care foods. The antidepressant drug is a liquid preparation, a solid preparation, a spray, an aerosol, or the like. The antidepressant compound according to the present invention is applied in preparation of antidepressant drugs and antidepressant health-care foods, and has a chemical structure different from those of existing antidepressant drugs. The anti-depressant compound has significant antidepressant activities without obvious toxic and side effects, contributes to large-scale promotion and use on the market, and has broad application prospects.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: August 27, 2019
    Assignee: ZHEJIANG ACADEMY OF MEDICAL SCIENCES
    Inventors: Yiping Ye, Xiaoyu Li, Yewei Yang, Zhengrong Zhao, Fengyang Chen, Shifang Xu, Wenhai Huang
  • Patent number: 10391105
    Abstract: The disclosure provides a method of treating a patient having postpartum depression, premenstrual dysphoric disorder, menopausal depression, or delirium tremens comprising administering an effective amount of an injectable neurosteroid formulation to the patient. In certain embodiments the injectable neurosteroid formulation is an injectable ganaxolone formulation. Two types of injectable neurosteroid formulations may be used in the disclosed methods. The first such formulation is an injectable formulation containing ganaxolone and sulfobutyl ether ?-cyclodextrin in a 1:1 inclusion complex. The second such formulation is an injectable neurossteroid formulation comprising a neurosteroid, preferably ganaxolone, but which may be a neurosteroid selected from allopregnanolone, ganaxolone, alphaxalone, alphadolone, hydroxydione, minaxolone, pregnanolone, tetrahydrocorticosterone, and combinations of the foregoing; a surface stabilizer selected from hydroxyl ethyl starch, dextran, and povidone; and a surfactant.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: August 27, 2019
    Assignee: MARINUS PHARMACEUTICALS INC.
    Inventors: Christopher Cashman, Jaakko Lappalainen, David A Czekai
  • Patent number: 10391106
    Abstract: Provided herein are 19-nor C3,3-disubstituted steroids of Formula (I): and pharmaceutically acceptable salts thereof; wherein , R1, R2, R3a, R3b, R4a, and R4b are as defined herein, and A is a carbon bound substituted or unsubstituted 5- to 6-membered heteroaryl ring as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: August 27, 2019
    Assignee: Sage Therapeutics, Inc.
    Inventors: Gabriel Martinez Botella, Boyd L. Harrison, Albert J. Robichaud, Francesco G. Salituro, Richard T. Beresis
  • Patent number: 10391107
    Abstract: The present invention includes a method of suppressing systemic immune response in a subject, the method comprising topically administering a pharmaceutically effective amount of a vitamin D analog to a subject in need thereof. The present invention further includes a method of treating an autoimmune disease in a subject, the method comprising topically administering a pharmaceutically effective amount of a vitamin D analog to a subject in need thereof.
    Type: Grant
    Filed: March 16, 2016
    Date of Patent: August 27, 2019
    Assignee: The Trustees of the University of Pennsylvania
    Inventor: Taku Kambayashi
  • Patent number: 10391108
    Abstract: Provided herein is a topical composition and related methods for making and using the composition. In a first aspect, the topical composition comprises minocycline, a magnesium salt, and a sulfite compound in a non-aqueous solvent. In yet another aspect, the topical composition comprises a tetracycline-class drug, a source of magnesium, a monohydric aliphatic alcohol, and a polyol, wherein (i) the ratio between the monohydric aliphatic alcohol and the propylene glycol is in the range of 1:1 to 99:1 by weight and (ii) the tetracycline-class drug is dissolved in the topical composition.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: August 27, 2019
    Assignee: BioPharmX, Inc.
    Inventors: Xin Chen, Maiko C. Hermsmeier, Diana Lac, Douglas W. Thomas, Noymi Yam, Akira Yamamoto
  • Patent number: 10391109
    Abstract: A method for treating fatty liver disease in a patient in need thereof, including a step of administering an effective amount of zoledronic acid. The fatty liver disease includes fatty liver disease caused by foodborne and hereditary factors, in particular non-alcoholic fatty liver. A dosage form of the zoledronic acid is an injection, a solution, a tablet, or a capsule.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: August 27, 2019
    Assignee: NANJING UNIVERSITY
    Inventors: Chaojun Li, Bin Xue, Shan Jiang, Qiaoli Tang
  • Patent number: 10391110
    Abstract: The present invention relates to a pharmaceutical composition containing ginsenoside F1 or Rh1 for preventing or treating vascular leak syndrome, to a method for treating vascular leak syndrome using the pharmaceutical composition, and to a food composition containing ginsenoside F1 or Rh1 for preventing or ameliorating vascular leak syndrome. The ginsenoside F1 or Rh1 provided in the present invention can promote angiogenesis and suppress vascular leakage, and thus can be widely utilized in the effective prevention or treatment of vascular leak syndrome.
    Type: Grant
    Filed: May 19, 2016
    Date of Patent: August 27, 2019
    Assignee: Intelligent Synthetic Biology Center
    Inventors: Ho Min Kim, Ji In Kang, Sun Chang Kim, Chang Hao Cui
  • Patent number: 10391111
    Abstract: Provided are a pharmaceutical composition for preventing or treating cervical cancer including gypenoside LXXV or a pharmaceutically acceptable salt thereof as an active ingredient, a method of preventing or treating cervical cancer including administering the pharmaceutical composition to a subject excluding humans, a health functional food composition for preventing or improving cervical cancer including gypenoside LXXV as an active ingredient, and a feed composition for preventing or improving cervical cancer including gypenoside LXXV as an active ingredient.
    Type: Grant
    Filed: June 21, 2016
    Date of Patent: August 27, 2019
    Assignee: Intelligent Synthetic Biology Center
    Inventors: Chang Hao Cui, Wan Taek Im, Sun Chang Kim
  • Patent number: 10391112
    Abstract: A method for treating a biological cell is disclosed. The method administers a mixture of a chemotherapeutic drug and a co-drug that facilitates delivery of the chemotherapeutic drug to the nucleus of the cell. Examples of co-drugs include cationic polymers, cationic lipids and cationic proteins. Cationic polymers include a polyethyleneimine (PEI), polylysine, a polybetaaminoester (PBAE), an ?-polylysine (EPL) including ?-poly-L-lysine (e-PLL), a polyarginine peptide, chitosan, a polyamidoamine dendrimer (PAMAM). Cationic lipids include 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP). Cationic proteins include protamine.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: August 27, 2019
    Assignee: NORTHWESTERN UNIVERSITY
    Inventors: Debra Auguste, Daxing Liu
  • Patent number: 10391113
    Abstract: Disclosed are a compound pharmaceutical composition containing Cichorium glandulosum Boiss et Hout as a lipid-lowering active ingredient and the use of the composition for preparing a drug for treating or preventing lipid metabolism disorders, wherein the composition comprises a pharmaceutically active ingredient and a pharmaceutically acceptable carrier, wherein the pharmaceutically active ingredient consists of quercetin-3-O-?-D-glucuronoside, isoquercitrin and quercetin at a molar ratio of 1.1-2.4:1.3-3.3:1.2-3.1.
    Type: Grant
    Filed: March 6, 2015
    Date of Patent: August 27, 2019
    Assignee: NANJING RUIYING RUNZE BIOPHARMAEUTICAL TECHNOLOGY CO., INC.
    Inventors: Jing Shang, Lin Ding, Guohong Qin, Tao Wang, Jun Liu, Yu Li, Ting He
  • Patent number: 10391114
    Abstract: Provided is a formulation and a method associated therewith for treating inflammation. The formulation includes therapeutically effective amounts of curcuminoids and two flavonoids. The two flavonoids include baicalin and catechin.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: August 27, 2019
    Assignee: Primus Pharmaceuticals, Inc.
    Inventors: Domenica Altavilla, Robert Levy
  • Patent number: 10391115
    Abstract: The present invention relates to a pharmaceutical composition for an anticancer adjuvant containing a receptor-interacting protein kinase-3 (RIP3) protein expression inducing agent or activator as an active ingredient. The present invention also provides a method for enhancing cancer cell death, comprising administering a RIP3 protein expression inducing agent or activator in combination with an anticancer drug to cancer cells. Additionally, the present invention relates to a method for screening an anticancer adjuvant which enhances anticancer drug sensitivity by promoting RIP3 expression; and a method for monitoring anticancer drug sensitivity based on RIP3 expression. Therefore, in the case of patients lacking RIP3 expression, the use of a conventional chemotherapeutic agent after inducing RIP3 expression by pretreatment with a demethylating agent may be an effective therapeutic strategy.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: August 27, 2019
    Assignee: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: You Sun Kim, Gi Bang Koo, Jung Ho Yun, Woo Jung Kim, Yu Na Jo
  • Patent number: 10391116
    Abstract: The present invention concerns nanoparticles functionalized with duplex RNA for a variety of uses, including but not limited to gene regulation. More specifically, the disclosure provides a new strategy for conjugating RNA to a nanoparticle to achieve increased stability and activity.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: August 27, 2019
    Assignee: NORTHWESTERN UNIVERSITY
    Inventors: Chad A. Mirkin, David A. Giljohann, Dwight S. Seferos, Andrew E. Prigodich, Pinal C. Patel
  • Patent number: 10391117
    Abstract: The present invention generally relates to treatment of iron-related conditions with iron carbohydrate complexes. One aspect of the invention is a method of treatment of iron-related conditions with a single unit dosage of at least about 0.6 grams of elemental iron via an iron carbohydrate complex. The method generally employs iron carbohydrate complexes with nearly neutral pH, physiological osmolarity, and stable and non-immunogenic carbohydrate components so as to rapidly administer high single unit doses of iron intravenously to patients in need thereof.
    Type: Grant
    Filed: April 10, 2015
    Date of Patent: August 27, 2019
    Assignee: Luitpold Pharmaceuticals, Inc.
    Inventors: Mary Jane Helenek, Marc L. Tokars, Richard P. Lawrence
  • Patent number: 10391118
    Abstract: Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain crosslinked amine polymers and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons and/or chloride ions from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: August 27, 2019
    Assignee: TRICIDA, INC
    Inventors: Gerrit Klaerner, Eric F. Connor, Randi K. Gbur, Matthew J. Kade, Paul H. Kierstead, Jerry M. Buysse, Michael J. Cope, Kalpesh N. Biyani, Son H. Nguyen, Scott M. Tabakman
  • Patent number: 10391119
    Abstract: Provided is a tear lipid layer stabilizer that is capable of stabilizing a tear lipid layer and allowing the tear lipid layer to sufficiently spread over a corneal surface, to thereby prevent the evaporation of a tear aqueous layer on the corneal surface, and hence is suitable for amelioration, alleviation, or treatment of evaporative dry eye symptoms caused by Meibomian gland dysfunction, an ophthalmic solution having blended therein the tear lipid layer stabilizer, and a tear lipid layer-stabilizing method using the tear lipid layer stabilizer. The tear lipid layer stabilizer includes a copolymer that has a weight-average molecular weight of from 10,000 to 5,000,000, and contains 10 mol % to 90 mol % of a constituent unit (A) based on 2-(meth)acryloyloxyethyl phosphorylcholine and 90 mol % to 10 mol % of a constituent unit (B) based on an alkyl group-containing (meth)acrylic monomer.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: August 27, 2019
    Assignee: NOF Corporation
    Inventors: Shunsuke Sakurai, Koji Miyamoto, Yoshihisa Shimamura, Nobuyuki Yamamoto
  • Patent number: 10391120
    Abstract: The present invention provides a treatment of acute respiratory distress syndrome (ARDS) in children using dosing of nitric oxide at low concentrations, such as less than 10 ppm.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: August 27, 2019
    Assignee: Mallinckrodt Hospital Products IP Limited
    Inventors: Jim Potenziano, Ronald Bronicki, James Baldassarre
  • Patent number: 10391121
    Abstract: Provided herein is a topical composition and related methods for making and using the composition. In a first aspect, the topical composition comprises a magnesium salt (e.g. magnesium chloride) dissolved in an anhydrous or non-aqueous solvent. Exemplary solvents comprise a monohydric aliphatic alcohol, and a polyol.
    Type: Grant
    Filed: May 3, 2018
    Date of Patent: August 27, 2019
    Assignee: BioPharmX, Inc.
    Inventor: Kin F. Chan
  • Patent number: 10391122
    Abstract: A non-pyrogenic preparation containing nanoparticles synthesized by magnetotactic bacteria for medical or cosmetic applications. The nanoparticles are constituted by a crystallized mineral central part including predominantly an iron oxide, as well as a surrounding coating without material from the magnetotactic bacteria.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: August 27, 2019
    Assignee: NANOBACTERIE
    Inventors: Edouard Alphandery, Mickael Durand-Dubief
  • Patent number: 10391123
    Abstract: The present invention provided an anticancer nano-silver composition for the treatment and prevention of cervical cancer. The composition contains nano-silver powder 3-200 mg/kg, carbomer 700-1000 mg/kg, triethanolamine 700-1000 mg/kg, glucose 2.8-3.2 g/kg, and water as remaining; of the nano-silver powder, wherein the purity of silver is ?99.99% and particle size is 1-5 nm. Experiments demonstrated that the anticancer nano-silver composition can be used to inhibit HeLa proliferation, and cause cell death. The anticancer nano-silver composition of the present invention can be used to manufacture medicaments for the treatment and prevention of cervical cancer.
    Type: Grant
    Filed: March 27, 2015
    Date of Patent: August 27, 2019
    Inventors: Jinjun Liu, Weiyi B. H. Situ, Qiangbai Li
  • Patent number: 10391124
    Abstract: Topical formulations for application to exposed body tissue.
    Type: Grant
    Filed: April 24, 2017
    Date of Patent: August 27, 2019
    Assignee: Aidance Skincare & Topical Solutions LLC
    Inventors: Aharon Weissman, Perry Antelman, Shalom Lampert, David Goldsmith
  • Patent number: 10391125
    Abstract: Nanosecond pulsed electric field (nsPEF) treatments of a tumor are adjusted based on a size and type of the tumor to stimulate an immune response against the tumor and other tumors in the subject. Calreticulin expression on tumor cells can be detected to confirm treatment. An immune response biomarker can be measured, and further nsPEF treatments can be performed if needed to stimulate or further stimulate the immune response. Cancers that have metastasized may be treated by directly treating a tumor that is most accessible. The treatment can be combined with CD47-blocking antibodies, doxorubicin, CTLA-4-blocking antibodies, and/or PD-1-blocking antibodies. Electrical characteristics of nsPEF treatments can be based on the size, type, and/or strength of tumors and/or a quantity of tumors in the subject.
    Type: Grant
    Filed: September 26, 2018
    Date of Patent: August 27, 2019
    Assignee: PULSE BIOSCIENCES, INC.
    Inventors: Richard Lee Nuccitelli, Pamela S. Nuccitelli, Joanne Lum, Kaying Lui, Brian G. Athos, Mark P. Kreis, Zachary R. Mallon, Jon Berridge
  • Patent number: 10391126
    Abstract: The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising disrupted T cell receptor and/or HLA and comprising a chimeric antigen receptor. In certain embodiments, the compositions are employed allogeneically as universal reagents for “off-the-shelf treatment of medical conditions such as cancer, autoimmunity, and infection. In particular embodiments, the T cell receptor-negative and/or HLA-negative T cells are generated using zinc finger nucleases, for example.
    Type: Grant
    Filed: November 16, 2012
    Date of Patent: August 27, 2019
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Laurence J. Neil Cooper, Hiroki Torikai
  • Patent number: 10391127
    Abstract: Compositions and methods of promoting wound healing in a human by administering to the human mesenchymal stem cells in an effective amount.
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: August 27, 2019
    Assignee: Mesoblast International Sárl
    Inventors: Sudeepta Aggarwal, Mark F. Pittenger, Timothy Varney
  • Patent number: 10391128
    Abstract: The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: August 27, 2019
    Assignee: 4D Pharma Research Limited
    Inventors: Imke Elisabeth Mulder, Amy Beth Holt, Seanin Marie McCluskey, Grainne Clare Lennon, Suaad Ahmed
  • Patent number: 10391129
    Abstract: Microbiota restoration therapy compositions and methods for manufacturing, processing, and/or delivering microbiota restoration therapy compositions are disclosed. An example method for manufacturing a microbiota restoration therapy composition may include collecting a human fecal sample and adding a diluent to the human fecal sample to form a diluted sample. The diluent may include a cryoprotectant. The method may also include mixing the diluted sample with a mixing apparatus and filtering the diluted sample. Filtering may form a filtrate. The method may also include transferring the filtrate to a sample bag and sealing the sample bag.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: August 27, 2019
    Assignee: REBIOTIX, INC.
    Inventors: Lee A. Jones, Courtney R. Jones, Edwin J. Hlavka, Ryan D. Gordon
  • Patent number: 10391130
    Abstract: The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: August 27, 2019
    Assignee: 4D PHARMA RESEARCH LIMITED
    Inventors: George Grant, Angela Margaret Patterson, Imke Mulder, Seanin McCluskey, Emma Raftis
  • Patent number: 10391131
    Abstract: Disclosed are methods and compositions for the prevention and treatment of food allergy. In particular, described herein are microbial consortia, including minimal microbial consortia, that can prevent and/or cure food allergy. In certain embodiments, the consortia comprise certain members of the taxa Clostridiales and/or Bacteroidetes.
    Type: Grant
    Filed: March 5, 2019
    Date of Patent: August 27, 2019
    Assignees: THE BRIGHAM AND WOMEN'S HOSPITAL, INC., CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Talal A. Chatila, Lynn Bry, Georg Gerber, Azza Abdel-Gadir, Rima Rachid
  • Patent number: 10391132
    Abstract: The present disclosure relates to recombinant viral vectors for the treatment and prevention of cancer. Oncolytic viral vectors incorporate one or more of the following features: viral replication restriction by insertion of tumor-suppressive microRNA (miRNA) target sequences into the viral genome; disruption of oncogenic miRNA function; cancer microenvironment remodeling; and cancer cell targeting by incorporation of protease-activated antibodies into the viral particle.
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: August 27, 2019
    Assignee: ONCORUS, INC.
    Inventors: Kenneth P. Greenberg, Mitchell H. Finer
  • Patent number: 10391133
    Abstract: The present invention relates to a traditional Chinese medicine composition for regulating immunity and preparation method thereof, characterized in that the composition comprises raw materials such as Radix Panacis Quinquefolii, Ganoderma, fermented Cordyceps sinensis powder, Flos Rosae Rugosae, and Rhizoma Anemarrhenae and is prepared into various conventional pharmaceutical formulations through processes such as pulverization, water decoction and alcohol extraction. The traditional Chinese medicine composition is effective in preventing and treating allergic diseases, hepatitis B and AIDS, elevating leukocytes, preventing and treating radiation injury, reducing toxic and side effects resulting from radiotherapy and chemotherapy, improving the male sexual function, enhancing immunity of the human body and alleviating physical fatigue.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: August 27, 2019
    Assignee: JIANGZHONG PHARMACEUTICALS CO., LTD.
    Inventors: Hongguang Zhong, Minzhi Yi, Jianzhong Lu
  • Patent number: 10391134
    Abstract: The present invention is directed to compositions, uses and methods useful in the prevention or treatment of Candida infections, in particular Candida albicans infections and in particular recurrent Candida infections notably vaginal and oral or buccal candidiasis.
    Type: Grant
    Filed: April 23, 2015
    Date of Patent: August 27, 2019
    Assignee: PHARMALP SA
    Inventors: Philippe Meuwly, Christian Abbet, Bruno Schnyder, Jean-Martin Denis, Xavier Simonnet
  • Patent number: 10391135
    Abstract: A method of treating an amyloid disease by administration of cactus mucilage extract from Opuntia ficus-indicia is presented. Both gelling and non-gelling cactus mucilage extracts were found to induce changes in the secondary structures of the amyloid beta peptides thus interfering with formation of A? fibrils and aggregation of A? fibrils into plaques.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: August 27, 2019
    Assignee: University of South Florida
    Inventors: Norma A. Alcantar, David Morgan, Zeinab Veisi, Leonid Breydo, Vladimir N. Uversky, Ryan G. Toomey, Tunan Peng, Eva Stephanie Lobbens
  • Patent number: 10391136
    Abstract: It is demonstrated herein that the consumption of a composition prepared from lentil hulls changes the elastic properties of vessel walls. This means that administration of an effective amount of the composition over a suitable period of time lentils can reverse vascular remodeling, thereby restoring arterial compliance, whereas it was previously assumed that arterial remodeling was irreversible.
    Type: Grant
    Filed: June 27, 2016
    Date of Patent: August 27, 2019
    Assignee: Prairie Skyline Ventures
    Inventors: Carla G. Taylor, Peter Zahradka
  • Patent number: 10391137
    Abstract: An agent comprising one or more components selected from among cowberry derivatives, mangosteen derivatives, scutellaria root derivatives, inositol and inositol phosphate, as an active ingredient, is a novel agent that can effectively promote production of platelet-derived growth factor-BB (PDGF-BB), which contributes to production of mesenchymal stem cells and stabilization of stem cells.
    Type: Grant
    Filed: July 1, 2011
    Date of Patent: August 27, 2019
    Assignee: Shiseido Company, Ltd.
    Inventors: Tsutomu Soma, Masato Iino, Haruyo Yamanishi
  • Patent number: 10391138
    Abstract: Method of treating/managing Cancer is disclosed in various embodiments herein. The disclosed method includes the use of a combination of formulations and therapies that provide a holistic approach in treating or managing cancer. The method further includes practices of Ayurveda that facilitate in holistic healing of cancer patients.
    Type: Grant
    Filed: July 10, 2018
    Date of Patent: August 27, 2019
    Assignee: Muniyal Ayurvedic Research Centre
    Inventor: M Vijayabhanu Shetty
  • Patent number: 10391139
    Abstract: Blood Pressure Reduction with Dietary Supplements Abstract A daily dose of 6,000 mg of taurine, 1,000 mg of vitamin C, 150 mg of grape seed extract, 100 mg of vitamin B6, 2 mg of biotin, 2,000 IU of vitamin D3, and 87 mg of magnesium is shown to reduce blood pressure in hypertensive individuals by more than 10 mm Hg.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: August 27, 2019
    Assignee: Biotics Research Corporation
    Inventors: William S. Sparks, Daryl L. De Luca, Denis R. De Luca, Mark Houston
  • Patent number: 10391141
    Abstract: The invention discloses a composition comprising at least one N-acetyl lactosamine, at least one sialylated oligosaccharide and at least one fucosylated oligosaccharide, and a hydrolysate comprising partially and/or extensively hydrolyzed proteins, for use in the prevention and/or treatment of skin conditions and skin diseases. Preferably said composition is a starter infant formula. Said skin disease is in particular atopic dermatitis.
    Type: Grant
    Filed: November 21, 2011
    Date of Patent: August 27, 2019
    Assignee: Societe des Produits Nestle S.A.
    Inventor: Norbert Sprenger
  • Patent number: 10391142
    Abstract: The present disclosure provides methods of diagnosing painful intervertebral discs. The present disclosure also provides methods of treating a painful intervertebral disc.
    Type: Grant
    Filed: October 24, 2016
    Date of Patent: August 27, 2019
    Assignee: The Regents of the University of California
    Inventors: Zorica Buser, Jeffrey Charles Lotz
  • Patent number: 10391143
    Abstract: MOTS3 is a novel polypeptide. Methods of treating diseases such as diabetes, obesity, fatty liver, and cancer using MOTS3 and pharmaceutical compositions thereof are disclosed herein.
    Type: Grant
    Filed: August 27, 2018
    Date of Patent: August 27, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Pinchas Cohen, Changhan Lee
  • Patent number: 10391144
    Abstract: Embodiments of the present invention describe a method of changing the phenotype of monocytes and macrophages from a proinflammatory M1 phenotype to an anti-inflammatory M2 phenotype. The method can comprises providing a composition comprising a recombinant adeno-associated virus (rAAV) vector comprising an exogenous gene encoding ApoA-I Milano or a fragment thereof, and administering the composition to a mammal in need thereof to change the phenotype of monocytes or macrophages from a proinflammatory M1 phenotype to an anti-inflammatory M2 phenotype. By changing the phenotype of monocytes or macrophages from a proinflammatory M1 phenotype to an anti-inflammatory M2 phenotype, atherosclerosis can be treated. The present invention also describes a method of monitoring macrophage phenotypic switching and a method of assessing the efficacy of the treatment of atherosclerosis.
    Type: Grant
    Filed: August 28, 2018
    Date of Patent: August 27, 2019
    Assignee: Cedars-Sinai Medical Center
    Inventors: Prediman K. Shah, Behrooz Sharifi
  • Patent number: 10391145
    Abstract: The invention provides methods and materials for treating a seizure disorder such as epilepsy in a patient which employ a vector encoding a modified receptor, the so-called “DREADD” receptor being characterised by (i) a decreased responsiveness to its endogenous activating ligand (ii) a retained or enhanced responsiveness to an exogenous agonist. The modified receptor is expressed in neurons of a seizure focus in brain of the patient, and an exogenous agonist is administered which activates the modified receptor to reversibly alters the excitability of the neurons in the seizure focus leading to synaptic silencing or other inhibition.
    Type: Grant
    Filed: March 6, 2015
    Date of Patent: August 27, 2019
    Assignee: UCL BUSINESS PLC
    Inventors: Dennis Kaetzel, Matthew Charles Walker, Stephanie Schorge, Dimitri Michael Kullmann
  • Patent number: 10391146
    Abstract: Compositions and methods for inhibiting metastatic cancer cells. The compositions comprise nanoparticles which have incorporated therein leukocyte adhesion molecules and therapeutic molecules exposed on their surface. The nanoparticles may be provided attached to leukocytes. Introduction of these compositions in to the circulation of individuals results in inhibition and reduction of metastatic cancer cells.
    Type: Grant
    Filed: August 4, 2014
    Date of Patent: August 27, 2019
    Assignee: Cornell University
    Inventors: Michael R. King, Michael J. Mitchell, Kuldeepsinh Rana, Elizabeth C. Wayne, Chris B. Schaffer, Siddarth Chandrasekaran
  • Patent number: 10391147
    Abstract: Fusion proteins comprising cytokines, particularly insulin-like growth factor-1 (IGF-1) and variants thereof, epidermal growth factor (EGF), and other ligands to the EGF receptor, are provided. The fusion proteins further comprise SEQ ID NO:1 or other segments having lysine, glutamic acid, or aspartic acid residues. Uses for the fusion proteins are also provided.
    Type: Grant
    Filed: October 8, 2017
    Date of Patent: August 27, 2019
    Assignee: IGF Oncology, LLC
    Inventor: Hugh McTavish
  • Patent number: 10391148
    Abstract: Methods for preventing and/or inhibiting preterm labor in a pregnant subject, such as a human subject, are disclosed according to the invention including administering a therapeutically effective amount of a protein selected from the group consisting of: PIBF1, a fragment or variant thereof; IL-33, a fragment or variant thereof; and a combination of any two or more thereof. Pharmaceutical compositions for preventing and/or inhibiting preterm labor in a pregnant subject, such as a human subject, are disclosed according to the invention including a therapeutically effective amount of a protein selected from the group consisting of: PIBF1, a fragment or variant thereof; IL-33, a fragment or variant thereof; and a combination of any two or more thereof.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: August 27, 2019
    Assignee: Wayne State University
    Inventor: Kang Chen
  • Patent number: 10391149
    Abstract: The present application provides a composition and methods to enhance nerve regeneration utilizing at least one component of neural stem cells or IL12p40. The composition comprises neural stem cells and a neurotrophic factor, which is constructed by IL12p40 as at least one subunit. The methods to enhance nerve regeneration comprise providing a nerve regeneration composition comprising a neurotrophic factor containing IL12p40 as at least one subunit to a subject. The composition of the methods can further comprise neural stem cells.
    Type: Grant
    Filed: August 14, 2015
    Date of Patent: August 27, 2019
    Assignee: NATIONAL HEALTH RESEARCH INSTITUTES
    Inventors: Ing-Ming Chiu, Ya-Hui Chi, Don-Ching Lee
  • Patent number: 10391150
    Abstract: Embodiments are directed to compositions and methods of treating migraine and related neurological disorders. In certain aspects, methods and compositions are for reducing cortical spreading depression and/or suppressing the neurochemical basis for chronic and acute migraine events, and provide methods and pharmaceutical compositions related to both acute and preventive therapies for migraine events and related headaches.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: August 27, 2019
    Assignee: The Universit of Chicago
    Inventors: Richard Kraig, Aya Pusic, Heidi Mitchell, Yelena Grinberg, Marcia Kraig
  • Patent number: 10391151
    Abstract: In permeability lung edema, cardiogenic lung edema or neonatal respiratory distress, there is heterogeneous liquid distribution throughout the lungs. The excess alveolar liquid reduces gas exchange. Mechanical ventilation is used to improve gas exchange. In the presence of heterogeneous liquid distribution, there are surface tension-dependent stress concentrations in septa separating aerated from flooded alveoli. Mechanical ventilation, by inflating the lung above normal volumes, thus increasing surface tension above normal, exacerbates the stress concentrations and consequently injures, or exacerbates pre-existing injury of, the alveolar-capillary barrier. Any means of lowering surface tension should lessen ventilation injury of the lung. In the present invention, dilute exogenous surfactant solution or surfactant protein C solution interacts with albumin to lower surface tension, likely through effective promotion of surfactant lipid adsorption.
    Type: Grant
    Filed: June 27, 2016
    Date of Patent: August 27, 2019
    Assignee: The Trustees of the Stevens Institute of Technology
    Inventor: Carrie E. Perlman
  • Patent number: 10391152
    Abstract: The present invention provides methods of administering a clotting factor by a fixed dosing regimen; methods of reducing, ameliorating, or preventing one or more symptoms of a bleeding disease or disorder; and a kit comprising a dotting factor useful for a fixed dosing regimen. While plasma-derived and recombinant clotting factor products allow hemophilia patients to live longer and healthier, hemophilia still remains one of the most costly and complex conditions to manage.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: August 27, 2019
    Assignee: Bioverativ Therapeutics Inc.
    Inventors: Haiyan Jiang, Lei Diao, Shuanglian Li, Paula Cobb
  • Patent number: 10391153
    Abstract: The present invention provides a novel method of treatment for treating brain disorders that manifest oxidative stress by providing targeted populations of neurons with the ability to catabolize the acetylated amino acid derivative, N-acetylaspatic acid (NAA) and further supply extraphysiological levels of ATP to neurons via the targeted expression of the NAA catabolic enzyme aspartoacylase (ASPA) in neurons and astrocytes.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: August 27, 2019
    Assignee: Rowan University
    Inventors: Paola Leone, Jeremy Francis